Difficulty: Medium
Average Score: 65%
Practice
Which type of leukemia has been MOST likely developed in a 2-year-old child with Down syndrome in the neonatal period?
Correct answer
D
Rationale
In this scenario, the correct answer is D) AML M6. Acute Myeloid Leukemia (AML) is the most likely type of leukemia to develop in a 2-year-old child with Down syndrome in the neonatal period. Children with Down syndrome have a higher risk of developing AML compared to other types of leukemia. AML M6 specifically refers to acute erythroleukemia, which is characterized by the presence of both myeloid and erythroid blasts in the bone marrow.
Option A, ALL (Acute Lymphoblastic Leukemia), is less likely in this case as Down syndrome is not strongly associated with ALL. Option B, CML (Chronic Myeloid Leukemia), is a chronic leukemia that typically occurs in adults, making it less likely in a 2-year-old child. Option C, AML M1, is a subtype of AML but is less common in children with Down syndrome compared to AML M6.
Educationally, understanding the association between Down syndrome and specific types of leukemia is crucial for nursing students caring for pediatric patients. This knowledge helps in early identification, appropriate treatment, and better outcomes for children with Down syndrome who may develop leukemia. It also highlights the importance of personalized care based on both the patient's age and underlying conditions.
Option A, ALL (Acute Lymphoblastic Leukemia), is less likely in this case as Down syndrome is not strongly associated with ALL. Option B, CML (Chronic Myeloid Leukemia), is a chronic leukemia that typically occurs in adults, making it less likely in a 2-year-old child. Option C, AML M1, is a subtype of AML but is less common in children with Down syndrome compared to AML M6.
Educationally, understanding the association between Down syndrome and specific types of leukemia is crucial for nursing students caring for pediatric patients. This knowledge helps in early identification, appropriate treatment, and better outcomes for children with Down syndrome who may develop leukemia. It also highlights the importance of personalized care based on both the patient's age and underlying conditions.